Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy plus SBRT with or without durvalumab and oleclumab in luminal B breast cancer
2018-004165-13Phase 2Active
- Sponsor
- Institut Jules Bordet
- Start
- Apr 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab, oleclumab, paclitaxel, cyclophosphamide and doxorubicin in Luminal B breast cancer (3 arms), sponsored by Institut Jules Bordet. Primary endpoint: Safety run-in endpoints. Started Apr 2019; status: active.
02
Drugs
durvalumaboleclumabpaclitaxelcyclophosphamidedoxorubicin
03
Conditions
Luminal B breast cancer
Beyond the preview
Go deeper on 2018-004165-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004165-13.